Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1147
Shown on this page
12
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within NYU Langone Health, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 913–924 of 1,147 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Not applicable Interventional

Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With FANS Access Sheaths

NCT07516106
Site status not listed — check the official record
View directory record Official record
Conditions
Kidney Stone
Interventions
Moses Holmium:YAG laser, Thulium:YAG laser
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Recruiting Early Phase 1 Interventional

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

NCT06961630
Status at this site: Recruiting
View directory record Official record
Conditions
Myocardial Injury After Noncardiac Surgery
Interventions
Rivaroxaban, Atorvastatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Recruiting Not applicable Interventional

The Benefits Of Cryoablation In Patients Undergoing Total Knee Arthroplasty

NCT06991231
Status at this site: Recruiting
View directory record Official record
Conditions
Post-Operative Pain, Total Knee Arthroplasty
Interventions
Total knee arthroplasty (TKA), Cryoablation
Procedure · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

NCT03428802
Site status not listed — check the official record
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
137
States / cities
Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847
Site status not listed — check the official record
View directory record Official record
Conditions
Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
Interventions
INCB057643, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Not applicable Interventional

Postoperative Immobilization and Physical Therapy Following Volar Locked Plating for Distal Radius Fractures

NCT04324580
Site status not listed — check the official record
View directory record Official record
Conditions
Distal Radius Fracture
Interventions
Splint, Formal Physical Therapy, Self directed physical therapy, Soft dressing (No Splint)
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Recruiting Not applicable Interventional

A Study of a Novel EEG Neurofeedback System for PTSD Treatment

NCT06770998
Status at this site: Recruiting
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
EEG-neurofeedback training, Sham training
Device
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Biomarkers for Exercise

NCT07340281
Status at this site: Recruiting
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Exercise Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Phase 4 Interventional

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair

NCT04852783
Site status not listed — check the official record
View directory record Official record
Conditions
Aneurysm, Intracranial
Interventions
Contour Neurovascular System
Device
Lead sponsor
Cerus Endovascular, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
20
States / cities
Englewood, Colorado • Jacksonville, Florida • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Not applicable Interventional

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

NCT06984523
Site status not listed — check the official record
View directory record Official record
Conditions
Leptomeningeal Metastasis
Interventions
Varian Eclipse
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 6, 2026, 11:35 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

NCT02138734
Site status not listed — check the official record
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2039
U.S. locations
72
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 6, 2026, 11:35 AM EST

About this NYU Langone Health institution page

What this page lists
ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.